Zentalis Pharmaceuticals Inc · Q1 2020 earnings

Briefing

Zentalis reported financial results for the first quarter ended March 31, 2020, and highlighted recent corporate accomplishments.

Zentalis Pharmaceuticals reported a net loss of $16.2 million for Q1 2020, compared to a net loss of $8.7 million for the same period in 2019. The company's cash and cash equivalents were $63.7 million as of March 31, 2020. They completed an initial public offering, raising approximately $190.0 million in gross proceeds.

• Completed initial public offering, raising approximately $190.0 million in gross proceeds.
• FDA cleared the Company’s IND application for ZN-d5, an investigational oral selective inhibitor of B-cell lymphoma 2 (BCL-2).
• Cash and cash equivalents totaled $63.7 million as of March 31, 2020.
• Net loss for the first quarter of 2020 was $16.2 million.

Headline financials

Revenue & EPS history

Company expects that its existing cash and cash equivalents, together with the net proceeds from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.